Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
19 hedge funds and large institutions have $1.28M invested in Agile Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 21 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
47% less funds holding
Funds holding: 36 → 19 (-17)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
81% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 21
99% less capital invested
Capital invested by funds: $182M → $1.28M (-$181M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$310K |
| 2 |
Jane Street
New York
|
+$268K |
| 3 |
Citigroup
New York
|
+$168K |
| 4 |
Two Sigma Investments
New York
|
+$132K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$69.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$953K |
| 2 |
D.E. Shaw & Co
New York
|
-$460K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$194K |
| 4 |
State Street
Boston,
Massachusetts
|
-$61K |
| 5 |
FCBT
First Citizens Bank & Trust
Raleigh,
North Carolina
|
-$42K |
AGRX Hedge Fund Activity: Q2 2022 in Review
19 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2022, worth a combined $1.28M — down 99% from $182M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AGRX and 4 opened new positions — a net loss of 17 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $310K. The largest seller was Armistice Capital, exiting entirely with an estimated $953K sold.
- 19 institutional investors held Agile Therapeutics (AGRX) as of Q2 2022, down from 36 in Q1 2022.
- Funds reported $1.28M of Agile Therapeutics stock for Q2 2022, down 99% quarter-over-quarter.
- 4 funds opened new Agile Therapeutics positions in Q2 2022 and 21 closed out, a net change of -17 holders.
- The largest Agile Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $310K added.
- The largest Agile Therapeutics seller in Q2 2022 was Armistice Capital, an estimated $953K sold.
Based on aggregated 13F filings for Q2 2022.